FD Technologies Reports Strong FY25 Growth and Recommends £570m Takeover Offer
FD Tech announces KX's 33% ACV growth and £81.8m ARR, while board recommends £570m takeover offer at 40% share premium.
This article covers information on FD Technologies PLC.
LON:FDPA Transformative Year for FD Technologies
Well now, this isn’t your average RNS announcement. FD Technologies has just dropped a financial double-whammy: impressive FY25 results and a recommended £570m takeover. Let’s cut through the noise and unpack what really matters for investors.
The Headline Acts: Growth & Takeover
Two seismic developments stand out:
- KX’s Stellar Performance: The crown jewel (now the sole operation after divestments) smashed expectations with 33% ACV growth and £81.8m ARR – crossing the $100m milestone.
- Takeover Endorsement: The Board unanimously recommends TA’s £24.50/share cash offer, valuing FD Technologies at £570m. That’s a 40% premium to the pre-announcement share price.
KX: The Engine Driving Value
Strip away the corporate restructuring, and KX’s operational excellence shines:
Financial Punchlines
- 🔥 ACV Added: £18.0m (up 33% YoY) – top end of guidance
- 🚀 ARR: £81.8m (up 13%) – first time >$100m
- 💸 Cash EBITDA Loss: £14.6m (improved from £18.8m loss)
- 🏦 Net Cash: £55.1m (vs net debt of £18.5m last year)
Strategic Shifts
The real story? KX is successfully pivoting beyond financial services. 35% of new ACV came from sectors like aerospace, defence, and industrial IoT. Their collaboration with NVIDIA and cloud partners isn’t just PR fluff – it’s driving tangible client wins in semiconductor manufacturing.
The Takeover Rationale: Why TA? Why Now?
This isn’t a distress sale. The Board’s endorsement signals:
- Recognition that KX’s AI/data platform needs deeper pockets to maximise its $8bn+ market opportunity
- TA’s proven track record in scaling global software businesses
- A premium valuation that crystallises value after the strategic divestments
As CEO Seamus Keating noted: “TA is a valuable partner with a shared commitment to enhancing KX’s business.” Translation: They’ll accelerate what we’ve started.
Divestments & Capital Allocation
The strategic pruning deserves applause:
- ✅ First Derivative sold to EPAM for £230m
- ✅ MRP merged with CONTENTgine (retaining 49% stake)
- ✅ £120m returned to shareholders via tender offer
This surgical focus leaves KX as a pure-play AI/analytics business with a war chest.
Roadmap Ahead: Efficiency Meets Growth
Management’s guidance is refreshingly specific:
- 📈 FY26: At least 20% ARR growth
- ⚖️ FY27: Positive Cash EBITDA targeted
The emphasis is on “efficient growth” – scaling without the cash bonfire. With net cash and simplified operations, these targets look credible.
The Investor’s Lens
Three key implications:
- Takeover premium: At £24.50/share, TA is paying for KX’s future potential, not just current metrics
- Validation: The deal endorses KX’s tech leadership in real-time data/AI
- Upside potential: If shareholders reject the offer, execution on FY26 targets could drive further re-rating
Frankly, this RNS shows a management team executing strategic plays like chess masters. They’ve simplified the business, returned cash, and positioned KX for its next growth phase – whether under public markets or TA’s stewardship. The £570m question: will shareholders cash their chips or bet on continued solo growth? Either way, KX remains one to watch.
Related
Keep reading
Investing
Ten Technologies Preliminary Results 2026: Record EBITDA and Member Growth
Ten Technologies delivered record 2026 results as active members rose 23% and adjusted EBITDA increased 10% to £16.1 million.
JoshuaNovember 11, 2026
Investing
Winvia Entertainment completes The Online Giveaway Guys acquisition
Winvia Entertainment has completed its purchase of The Online Giveaway Guys' business and key assets, excluding liabilities, cash and receivables.
JoshuaNovember 10, 2026
Investing
RUA Life Sciences reaches positive adjusted EBITDA as Structural Heart spin-out reshapes the group
RUA Life Sciences expects £5.5 million revenue and £0.3 million adjusted EBITDA, but ABISS weakness and lower cash warrant attention.
JoshuaNovember 9, 2026
Last updated
Category
InvestingLikes
Star Rating
No ratings yet
Comments
No comments yet - start the conversation.